research Delayed granulomatous eruption of the nose associated with ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
Search
for
Sort by
Research
120-150 / 1000+ results
research PERICARDIAL EFFUSIONS ASSOCIATED WITH MINOXIDIL
research Evidence that mirex promotes a unique population of epidermal cells that cannot be distinguished by their mutant Ha-ras genotype
Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.
research Skin, eye and other problems
Some eczema treatments may cause conjunctivitis, many people have sensitive eyes, air pollution can increase skin wrinkles, hair loss medication does not affect sexual function, and dermatologists can help identify torture signs on refugees' skin.
research Rejuvenation by Design: Building Cosmetic Products with Extracellular Vesicle Technology, the Example of Exo.Reset®
Exo.Reset® uses extracellular vesicle technology for skin rejuvenation.
research Compounded topical finasteride-related AEs
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Latanoprost
A woman got a scalp condition from using latanoprost, but it improved after stopping the drug and starting other treatments.
research Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
research The management of EGFR inhibitor adverse events: a case series and treatment paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
research Inhibition of 5α-Reductase, IL-6 Secretion, and Oxidation Process of Equisetum debile Roxb. ex Vaucher Extract as Functional Food and Nutraceuticals Ingredients
Equisetum debile extract may help with hair loss by inhibiting enzymes and reducing inflammation.
research UK High Court Revokes Escitalopram UK Patent; Validity of Second Medical use Claims Based on Dosage Regimes in the UK; Stay of Proceedings in the UK Courts Pending EPO Opposition Proceedings
The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
research Antibacterials/corticosteroids/minoxidil
research Reporting on Adverse Clinical Events
Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
research A Male with an Erythema, Pustules, and Crusts on the Scalp
A rare scalp condition was successfully treated with specific medications after 9 months.
research Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling
Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
research Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Cutaneous Drug Reaction Case Reports
In 2002, various skin reactions were reported due to different drugs, including allergies, hair loss, skin lesions, and other skin conditions.
research Retinoids - new uses and new synthetic agents
New retinoids are effective for various skin conditions and are being developed to have fewer side effects.
research Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
Iressa often causes skin issues like acne and dryness in lung cancer patients.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research MICROEMULSION-BASED FLUSHING FLUID FOR EFFECTIVE REMOVAL OF FILTER CAKE IN WELLS CEMENTATION
The microemulsion-based fluid effectively removes mud cake during well cementation.
research 842Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS)
research Novel micelle formulations to increase cutaneous bioavailability of azole antifungals
New micelle solutions greatly improve skin delivery of certain antifungal drugs.